Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions

Atherosclerosis

Volumn 190, Issue 2, 2007, Pages 264-270

  Tran, Phan Kiet ^a   Agardh, Hanna E ^a   Tran Lundmark, Karin ^a   Ekstrand, Johan ^a   Roy, Joy ^a,b   Henderson, Bimma ^a   Gabrielsen, Anders ^a   Hansson, Göran K ^a   Swedenborg, Jesper ^a   Paulsson Berne, Gabrielle ^a   Hedin, Ulf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Carotid stenosis; Heparan sulfate; Microarray; Perlecan

Indexed keywords

AGRIN; COLLAGEN; COLLAGEN 18; PERLECAN; PROTEOCHONDROITIN SULFATE; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; VERSICAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; CAROTID ARTERY DISEASES; CAROTID STENOSIS; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA;

EID: 33846050448     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.03.010     Document Type: Article

References (47)

1. Engelberg H. Endogenous heparin activity deficiency: the 'missing link' in atherogenesis?. Atherosclerosis 159 (2001) 253-260
2. Lusis A.J., Fogelman A.M., and Fonarow G.C. Genetic basis of atherosclerosis. Part II. Clinical implications. Circulation 110 (2004) 2066-2071
3. Lusis A.J., Fogelman A.M., and Fonarow G.C. Genetic basis of atherosclerosis. Part I. New genes and pathways. Circulation 110 (2004) 1868-1873
4. Pillarisetti S., Paka L., Obunike J.C., Berglund L., and Goldberg I.J. Subendothelial retention of lipoprotein(a) evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 100 (1997) 867-874
5. Hayashi K., Madri J.A., and Yurchenco P.D. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan. J Cell Biol 119 (1992) 945-959
6. Clowes A.W., and Karnowsky M.J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265 (1977) 625-626
7. Bingley J.A., Hayward I.P., Campbell J.H., and Campbell G.R. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. J Vasc Surg 28 (1998) 308-318
8. Iozzo R.V., Cohen I.R., Grassel S., and Murdoch A.D. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302 Pt 3 (1994) 625-639
9. Murdoch A.D., Liu B., Schwarting R., Tuan R.S., and Iozzo R.V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42 (1994) 239-249
10. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol 8 (1996) 618-624
11. Segev A., Nili N., and Strauss B.H. The role of perlecan in arterial injury and angiogenesis. Cardiovasc Res 63 (2004) 603-610
12. Koyama N., Kinsella M.G., Wight T.N., Hedin U., and Clowes A.W. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. Circ Res 83 (1998) 305-313
13. Lundmark K., Tran P.K., Kinsella M.G., Clowes A.W., Wight T.N., and Hedin U. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate. J Cell Physiol 188 (2001) 67-74
14. Garl P.J., Wenzlau J.M., Walker H.A., Whitelock J.M., Costell M., and Weiser-Evans M.C. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res 94 (2004) 175-183
15. Kinsella M.G., Irvin C., Reidy M.A., and Wight T.N. Removal of heparan sulfate by heparinase treatment inhibits FGF-2-dependent smooth muscle cell proliferation in injured rat carotid arteries. Atherosclerosis 175 (2004) 51-57
16. Nugent M.A., Nugent H.M., Iozzo R.V., Sanchack K., and Edelman E.R. Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. Proc Natl Acad Sci USA 97 (2000) 6722-6727
17. Tran P.K., Tran-Lundmark K., Soininen R., Tryggvason K., Thyberg J., and Hedin U. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res 94 (2004) 550-558
18. Walker H.A., Whitelock J.M., Garl P.J., Nemenoff R.A., Stenmark K.R., and Weiser-Evans M.C. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell 14 (2003) 1941-1952
19. Engelberg H. Correlation of plasma heparin levels with serum lipoproteins. Acta Med Scand 151 (1955) 161-166
20. Hollmann J., Schmidt A., von Bassewitz D.B., and Buddecke E. Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis 9 (1989) 154-158
21. Murata K., and Yokoyama Y. Acidic glycosaminoglycan, lipid and water contents in human coronary arterial branches. Atherosclerosis 45 (1982) 53-65
22. Murata K., Murata A., and Yoshida K. Heparan sulfate isomers in cerebral arteries of Japanese women with aging and with atherosclerosis--heparitinase and high-performance liquid chromatography determinations. Atherosclerosis 132 (1997) 9-17
23. Edwards I.J., Wagner J.D., Vogl-Willis C.A., Litwak K.N., and Cefalu W.T. Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol 3 (2004) 6
24. Edwards I.J., and Wagner W.D. Cell surface heparan sulfate proteoglycan and chondroitin sulfate proteoglycan of arterial smooth muscle cells. Am J Pathol 140 (1992) 193-205
25. Kunjathoor V.V., Chiu D.S., O'Brien K.D., and LeBoeuf R.C. Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 462-468
26. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379-87.
27. Irizarry R.A., Bolstad B.M., Collin F., Cope L.M., Hobbs B., and Speed T.P. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31 (2003) e15
28. Barber A.J., and Lieth E. Agrin accumulates in the brain microvascular basal lamina during development of the blood-brain barrier. Dev Dyn 208 (1997) 62-74
29. Halfter W., Dong S., Schurer B., and Cole G.J. Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273 (1998) 25404-25412
30. Wight T.N., and Merrilees M.J. Proteoglycans in atherosclerosis and restenosis: key roles forversican. Circ Res 94 (2004) 1158-1167
31. Kolodgie F.D., Burke A.P., Farb A., et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol 22 (2002) 1642-1648
32. Geary R.L., Wong J.M., Rossini A., Schwartz S.M., and Adams L.D. Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 22 (2002) 2010-2016
33. Evanko S.P., Raines E.W., Ross R., Gold L.I., and Wight T.N. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol 152 (1998) 533-546
34. Cardoso L.E., and Mourao P.A. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL. Arterioscler Thromb 14 (1994) 115-124
35. Talusan P., Bedri S., Yang S., et al. Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry. Mol Cell Proteomics 4 (2005) 1350-1357
36. Bingley J.A., Hayward I.P., Campbell G.R., and Campbell J.H. Relationship of glycosaminoglycan and matrix changes to vascular smooth muscle cell phenotype modulation in rabbit arteries after acute injury. J Vasc Surg 33 (2001) 155-164
37. Kinsella M.G., Tran P.K., Weiser-Evans M.C., Reidy M., Majack R.A., and Wight T.N. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol 23 (2003) 608-614
38. Hedin U., Roy J., and Tran P.K. Control of smooth muscle cell proliferation in vascular disease. Curr Opin Lipidol 15 (2004) 559-565
39. Liuzzo J.P., Petanceska S.S., Moscatelli D., and Devi L.A. Inflammatory mediators regulate cathepsin S in macrophages and microglia: a role in attenuating heparan sulfate interactions. Mol Med 5 (1999) 320-333
40. Sasaki N., Higashi N., Taka T., Nakajima M., and Irimura T. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate. J Immunol 172 (2004) 3830-3835
41. Makatsori E., Lamari F.N., Theocharis A.D., et al. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res 23 (2003) 3303-3309
42. Camejo G., Hurt-Camejo E., Wiklund O., and Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 139 (1998) 205-222
43. Williams K.J. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr Opin Lipidol 12 (2001) 477-487
44. Iozzo R.V., Pillarisetti J., Sharma B., et al. Structural and functional characterization of the human perlecan gene promoter. Transcriptional activation by transforming growth factor-beta via a nuclear factor 1-binding element. J Biol Chem 272 (1997) 5219-5228
45. Yamazaki M., Cheng J., Hao N., et al. Basement membrane-type heparan sulfate proteoglycan (perlecan) and low-density lipoprotein (LDL) are co-localized in granulation tissues: a possible pathogenesis of cholesterol granulomas in jaw cysts. J Oral Pathol Med 33 (2004) 177-184
46. Pillarisetti S. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity. Trends Cardiovasc Med 10 (2000) 60-65
47. Vikramadithyan R.K., Kako Y., Chen G., et al. Atherosclerosis in perlecan heterozygous mice. J Lipid Res 45 (2004) 1806-1812